CN112353815B - Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof - Google Patents
Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof Download PDFInfo
- Publication number
- CN112353815B CN112353815B CN202011165868.9A CN202011165868A CN112353815B CN 112353815 B CN112353815 B CN 112353815B CN 202011165868 A CN202011165868 A CN 202011165868A CN 112353815 B CN112353815 B CN 112353815B
- Authority
- CN
- China
- Prior art keywords
- micro
- nano fiber
- fiber membrane
- extracellular vesicles
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002121 nanofiber Substances 0.000 title claims abstract description 127
- 239000012528 membrane Substances 0.000 title claims abstract description 120
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 40
- 239000007853 buffer solution Substances 0.000 claims abstract description 21
- 230000037314 wound repair Effects 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002791 soaking Methods 0.000 claims abstract description 13
- 230000004048 modification Effects 0.000 claims abstract description 9
- 238000012986 modification Methods 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 238000010041 electrostatic spinning Methods 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 238000009832 plasma treatment Methods 0.000 claims description 3
- 239000000232 Lipid Bilayer Substances 0.000 claims description 2
- 238000009830 intercalation Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000009941 weaving Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 238000012512 characterization method Methods 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- -1 amino, hydroxyl Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 101150035777 sev gene Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4382—Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/70—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres
- D04H1/72—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged
- D04H1/728—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a micro-nano fiber membrane with an extracellular vesicle slow-release function, and a preparation method and application thereof. The fiber membrane comprises a micro-nano fiber membrane, PEGylated phospholipid and extracellular vesicles; the micro-nano fiber membrane is connected with one end of the PEGylated phospholipid, and the extracellular vesicles are connected with the other end of the PEGylated phospholipid. The method comprises the following steps: and (3) carrying out surface modification on the micro-nano fiber membrane, soaking the micro-nano fiber membrane in a buffer solution containing PEGylated phospholipid, carrying out grafting reaction, and soaking the micro-nano fiber membrane in the buffer solution containing extracellular vesicles to obtain the micro-nano fiber membrane with the extracellular vesicles slow release function. The preparation method is simple, the reaction conditions are mild, the prepared micro-nano fiber membrane not only has good biocompatibility, but also can release extracellular vesicles rich in various bioactive factors to the wound surface, is beneficial to comprehensively improving pathological microenvironment of the wound surface, activates cells to participate in repair, and promotes the repair of the wound surface which is difficult to heal chronically. Is expected to be applied to the field of wound repair.
Description
Technical Field
The invention belongs to the field of biomedical materials, and particularly relates to a micro-nano fiber membrane with an extracellular vesicle slow-release function, and a preparation method and application thereof.
Background
Wound healing is a complex process that can be roughly divided into 4 distinct but overlapping phases: clotting phase, inflammatory phase, proliferative phase, remodelling phase. However, many pathological factors including bacterial infection and foreign body reaction in clinic lead to the destruction of the normal physiological repair process of the wound surface, thus forming a wound surface which is difficult to heal. The root cause of the chronic difficult-to-heal wound repair difficulty is that the local physiological environment of the wound is seriously unbalanced, so that the clinical requirement cannot be met by delivering (loading) a single bioactive factor, thereby comprehensively improving the pathological microenvironment of the wound, activating cells to participate in repair and recovering the wound repair process, being the key for realizing the difficult-to-heal wound repair and also being the research and development trend of a new generation of wound repair material.
Extracellular vesicles include exosomes (exosomes), microvesicles (microvesicles) and apoptotic bodies (apoptoticbodies), containing large amounts of biologically active substances such as proteins, (growth factors, cytokines etc.), DNA, RNA and lipids etc., affecting target cell behaviour mainly by delivering self-carried contents (cargo), and in addition may also function by membrane surface molecules interacting with target cell surface receptors. Compared with stem cell therapy, the method has the advantages of smaller immunogenicity, more stable physicochemical properties and the like, and has great potential in the field of chronic refractory wound repair.
Due to the increasing demand for nanotechnology, electrospinning technology has received great attention. The electrostatic spinning nanofiber has a high specific surface area and high porosity because of the bionic natural extracellular matrix nanofiber structure, and has a huge prospect in the field of wound repair.
The extracellular vesicles are loaded on the micro-nano fiber repair material, so that bioactive factors can be delivered to the defect of the tissue through the extracellular vesicles, the purpose of comprehensively improving the pathological microenvironment of the defect and activating body cells to participate in repair of the defect is achieved (MSC-derived sEVs enhance patency and inhibit calcification of syntheticvascular grafts by immunomodulation in a rat model of hyperlipidemia). However, most of the existing materials load extracellular vesicles in a direct physical adsorption mode, and the materials and the extracellular vesicles lack effective interaction, so that the problems of low load, difficult enrichment and stopping exist.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention aims to provide a micro-nano fiber membrane with an extracellular vesicle slow-release function, and a preparation method and application thereof.
The invention provides a preparation method of a micro-nanofiber-based wound repair material with an extracellular vesicle slow-release function. According to the invention, the PEG phospholipid is grafted on the surface of the micro-nano fiber membrane, so that the extracellular vesicles are effectively loaded, and the slow release of the extracellular vesicles on the wound surface is realized.
The object of the invention is achieved by at least one of the following technical solutions.
The invention provides a micro-nanofiber membrane with an extracellular vesicle slow-release function (micro-nanofiber-based chronic refractory wound repair material with a slow-release function), which comprises a micro-nanofiber membrane (a micro-nanofiber membrane obtained by an electrostatic spinning technology), PEGylated phospholipid and extracellular vesicles; the micro-nanofiber membrane is attached to a pegylated phospholipid, which is attached (loaded) to an extracellular vesicle. And grafting PEG phospholipid with a long-chain structure on the surface of the micro-nano fiber membrane, wherein the PEG phospholipid can realize the loading of extracellular vesicles.
Further, the micro-nano fiber membrane is an electrospun polymer; the micro-nano fiber membrane is made of more than one of L-polylactic acid (PLLA), polylactic acid-glycolic acid copolymer (PLGA), polycaprolactone (PCL) and the like; the diameter of the micro-nano fiber membrane is 400-2000nm.
Further, the PEGylated phospholipid is a hydrophobic phospholipid connected by a PEG chain; the chain length of the PEG chain is 500-5000; the PEGylated phospholipid is connected with a group on the surface of the micro-nanofiber membrane; the groups on the surface of the micro-nano fiber membrane are more than one of carboxyl, amino, hydroxyl and the like. The PEGylated phospholipid is connected with groups (such as carboxyl, amino, hydroxyl and the like) capable of reacting with the groups on the surface of the micro-nanofiber membrane through a PEG chain.
Further, the pegylated phospholipids are capable of intercalating into lipid bilayers of extracellular vesicle membranes via hydrophobic interactions.
Further, the extracellular vesicles are one or more of exosomes (exosomes), microvesicles (microvesicles) and apoptotic bodies (apoptotics); the extracellular vesicles have a diameter of 50-1000nm.
The invention provides a method for preparing the micro-nano fiber membrane with the extracellular vesicle slow-release function, which comprises the following steps:
(1) Preparing micro-nano fibers by an electrostatic spinning method, and weaving the micro-nano fibers into a micro-nano fiber film;
(2) Carrying out surface modification treatment on the micro-nanofiber membrane in the step (1) by using plasma treatment, wet chemical method and other technologies, so that groups (such as amino, carboxyl, hydroxyl and the like) capable of reacting with PEGylated phospholipid are generated on the surface of the micro-nanofiber membrane, and the groups are activated to obtain a modified micro-nanofiber membrane;
(3) Soaking the modified micro-nano fiber membrane in the step (2) in a buffer solution containing PEGylated phospholipid, performing grafting reaction in a shaking table, and taking out to obtain the micro-nano fiber membrane with the surface grafted with the PEGylated phospholipid;
(4) And (3) immersing the micro-nano fiber membrane grafted with the PEG phospholipid on the surface in the step (3) in a buffer solution containing extracellular vesicles to obtain the micro-nano fiber membrane with the extracellular vesicles sustained release function (the micro-nano fiber membrane loaded with the extracellular vesicles and having the extracellular vesicles sustained release function).
Further, the surface modification treatment method in the step (2) is one or more of plasma treatment and wet chemical method.
Further, in the buffer solution containing the PEGylated phospholipid in the step (3), the concentration of the PEGylated phospholipid is 2-10mg/mL, the pH value of the buffer solution containing the PEGylated phospholipid is 5.0-6.0, the time of the grafting reaction is more than or equal to 12 hours, and the rotating speed of a shaking table is 10-60rpm.
Preferably, the grafting reaction in step (3) takes from 12 to 24 hours.
Further, in the buffer solution containing the extracellular vesicles in the step (4), the concentration of the extracellular vesicles is 5-15 mug/ml, the pH value of the buffer solution containing the extracellular vesicles is 6.8-7.6, the temperature of the buffer solution containing the extracellular vesicles is 4-37 ℃, and the time of soaking the micro-nano fiber membrane grafted with the PEGylated phospholipid on the surface in the buffer solution containing the extracellular vesicles is more than or equal to 4 hours.
Preferably, the temperature of the buffer containing extracellular vesicles in step (4) is 4 ℃.
Preferably, the micro-nanofiber membrane grafted with PEGylated phospholipid on the surface in the step (4) is soaked in the buffer solution containing extracellular vesicles for 4-16 hours.
The invention provides an application of a micro-nano fiber membrane with an extracellular vesicle slow-release function in preparing a medicine or a carrier material of a bioactive substance for repairing a chronic wound surface.
Compared with the prior art, the invention has the following advantages and beneficial effects:
(1) The micro-nanofiber-based wound repair material prepared by the invention can effectively load extracellular vesicles, realize slow release of the extracellular vesicles, improve pathological microenvironment of wound and promote chronic difficult-to-heal wound repair;
(2) The preparation method of the micro-nanofiber-based wound repair material provided by the invention is simple to operate and mild in condition.
Drawings
FIG. 1a is a scanning electron microscope image of extracellular vesicles in example 1.
FIG. 1b is a graph showing the particle size distribution of extracellular vesicles in example 1.
FIG. 1c is a graph showing the results of the electrophoresis identification of extracellular vesicles in example 1.
Fig. 2 is a schematic diagram of a micro-nanofiber-based chronic refractory wound repair material with an extracellular vesicle slow-release function prepared in example 2.
FIG. 3 is a scanning electron microscope image of the micro-nanofiber membrane before and after the treatment in example 2.
FIG. 4 is an infrared plot of the micro-nanofiber membrane before and after treatment in example 2.
FIG. 5 is a graph showing the release rate of extracellular vesicles on a micro-nanofiber membrane in example 2.
FIG. 6 is a graph showing migration effect of fibroblasts in example 2.
FIGS. 7a and 7b are graphs showing proliferation results of fibroblasts and keratinocytes, respectively, in example 2.
FIGS. 8a, 8b and 8c are graphs showing the results of expression of the genes involved in wound repair of fibroblasts in example 2.
Fig. 9a, 9b, 9c and 9d are graphs showing polarization results of macrophages in example 2.
Detailed Description
The following examples are presented to further illustrate the practice of the invention, but are not intended to limit the practice and protection of the invention. It should be noted that the following processes, if not specifically described in detail, can be realized or understood by those skilled in the art with reference to the prior art. The reagents or apparatus used were not manufacturer-specific and were considered conventional products commercially available.
The following examples take rat-derived adipose mesenchymal stem cell-derived extracellular vesicles as an example, and extracellular vesicles were obtained and identified, but are not limited to adipose mesenchymal stem cells.
Example 1: preparation and identification of rat-derived adipose mesenchymal stem cell-derived extracellular vesicles
(1) The supernatant of rat adipose-derived mesenchymal stem cells was collected.
The proliferation medium of rat adipose-derived mesenchymal stem cells consisted of 10wt% fetal bovine serum, 1wt% diabody and alpha-MEM. The density of the plate is 20,000cells/cm 2 Algebraic p3-p5 are used. For the extraction of extracellular vesicles, the present invention was carried out by culturing with a medium containing no extracellular vesicles when the cell confluency reached 80%, the composition was 10wt% of fetal bovine serum containing no extracellular vesicles, 1wt% of diabody and 1wt% of alpha-MEM,cell culture medium was collected after two days of culture.
(2) Extraction of extracellular vesicles of rat adipose-derived mesenchymal stem cells.
Extracellular vesicles of rat adipose-derived mesenchymal stem cells are extracted by a series of gradient centrifugation at 4 ℃. (1) 300 Xg, 10 minutes, cells and debris were removed; (2) 2000 Xg, 10 minutes, dead cells and debris were removed; (3) 10000 Xg, 30 minutes, cell debris is removed; (4) 100000 Xg, 70 min, precipitation (extracellular vesicles and protein components) was seen; (5) discarding the supernatant, retaining the precipitate, and adding PBS buffer (the concentration is 0.01mol/L, and the concentration of the PBS buffer is 0.01mol/L below); (6) 100000 Xg, 70 minutes, the sediment was seen as a purer concentration of extracellular vesicles.
(3) Characterization of extracellular vesicles of rat adipose mesenchymal stem cells.
Three characterization methods were used in combination for extracellular vesicle characterization. Wherein Transmission Electron Microscopy (TEM) is used for extracellular vesicle morphology characterization; western blot (Western blot) was used for extracellular vesicle marker identification; nanoparticle Tracking (NTA) was used for particle size analysis.
(1) Particle size analysis: as shown in FIG. 1b, the particle size of the extracted material is in the range of 50-200 nm.
(2) Morphological characterization: as shown in fig. 1a, the extracted material has a saucer-like structure.
(3) Identification of the marker: as shown in FIG. 1c, the extracted material was positive for the vesicle membrane markers CD 9, CD 63, TSG 101 expression.
The extracted substance is determined to have an extracellular vesicle structure according to three experimental results of particle size distribution, morphological characterization and marker identification, and can be modified by hydrophobic insertion.
Example 2: preparation and characterization of PLLA micro-nanofiber membranes.
Referring to FIG. 2, the following example was performed by electrospinning L-polylactic acid (PLLA) and modifying DSPE-PEG-NH on PLLA micro-nanofiber membrane 2 The PEGylated phospholipids are used for example to modify extracellular vesicles, but not only for PLLA and DSPE-PEG-NH 2 。
DSPE-PEG-NH 2 The structural formula of (2) is as follows:
(1) And (3) preparing the micro-nano fiber membrane.
(1) Preparing a micro-nano fiber film: dissolving the L-polylactic acid (PLLA) in a solvent, spinning by electrostatic spinning equipment to obtain a PLLA micro-nano fiber membrane, and drying in vacuum for 48 hours to remove the residual organic solvent.
(2) Exposing carboxyl groups on the surface of the micro-nanofiber membrane: and placing the PLLA micro-nanofiber membrane prepared by the method on a shaking table, soaking the PLLA micro-nanofiber membrane in a NaOH solution to expose carboxyl groups on the surface of the micro-nanofiber membrane, and washing the PLLA micro-nanofiber membrane with ultrapure water for three times to obtain the micro-nanofiber membrane with exposed carboxyl groups.
(3) Activating carboxyl on the surface of the micro-nano fiber film: and placing the prepared micro-nanofiber membrane with exposed carboxyl on a shaking table, soaking in MES buffer solution (pH is 6.0) of EDC and NHS, activating the carboxyl on the surface of the micro-nanofiber membrane, and washing with ultrapure water for three times to obtain the micro-nanofiber membrane with activated carboxyl.
④DSPE-PEG-NH 2 Grafting: placing the prepared carboxyl activated micro-nanofiber membrane on a shaking table, and soaking in DSPE-PEG-NH 2 In MES buffer solution of (B), washing with ultrapure water for three times, sterilizing with alcohol and ultraviolet to obtain grafted DSPE-PEG-NH 2 Is a micro-nanofiber membrane.
(5) Extracellular vesicle-loaded: the obtained DSPE-PEG-NH is grafted 2 The micro-nano fiber membrane is soaked in PBS buffer solution containing sterile extracellular vesicles, and is rinsed twice by the PBS buffer solution to obtain the micro-nano fiber membrane with a slow release function.
The solvent used in the step (1) is hexafluoroisopropanol, and the mass volume ratio of the solvent to PLLA is 10:1g/mL.
The process parameters used in the step (1) are as follows: the temperature is 25 ℃, the relative humidity is 60%, the flow rate is 0.6mL/h, the needle head is vertical to the ground, the distance is 15cm, the spinning voltage is 12kV, the stainless steel roller is wrapped by tin paper to receive the nanofiber, the rotating speed of the roller is 1.5 revolutions per minute, and the spinning time is 15-20 minutes.
The concentration of NaOH solution in the step (2) is 0.1M, the soaking time is 15min, the temperature is room temperature, and the rotating speed of the shaking table is 50rpm.
The EDC concentration in the step (3) is 0.5mg/ml, the NHS concentration is 0.25mg/ml, the soaking time is 20min, the temperature is room temperature, and the rotation speed of the shaking table is 50rpm.
DSPE-PEG-NH in step (4) 2 The concentration was 10mg/ml, the soaking time was 16h, the temperature was room temperature, and the shaking table rotation speed was 50rpm.
The concentration of extracellular vesicles in step (5) was 10. Mu.g/ml, the soaking time was 6h, and the temperature was 4 ℃.
(2) Characterization of micro-nanofiber membranes.
The scanning electron microscope observes the DSPE-PEG-NH 2 Morphology features of modified PLLA micro-nanofiber membranes and unmodified PLLA micro-nanofiber membranes, infrared appearance was subjected to DSPE-PEG-NH 2 Chemical bond of modified PLLA micro-nanofiber membrane with unmodified PLLA micro-nanofiber membrane.
(1) Morphology observation: will go through DSPE-PEG-NH 2 Modified PLLA fiber membranes (PLLA-DSPE in FIG. 3) and unmodified PLLA fiber membranes (PLLA in FIG. 3) were attached to a sample stage with a conductive adhesive, and taken out after metal spraying for 60s, and photographed by an on-machine observation. The results are shown in FIG. 3. The fiber membrane diameter before modification is 867.7 +/-60 nm, the fiber diameter after modification is 734.8 +/-80 nm, and no obvious difference exists; and the globular grafts can be seen on the fiber membrane after modification.
(2) Chemical bond change: to further confirm grafting, the mixture was subjected to a 0.1M NaOH shaker at 50rpm for 15min, 0.5mol/LEDC and 0.25mol/LNHS shaker at 50rpm for 20min, 10g/ml DSPE-PEG-NH 2 The shaking table 50rpm was used to treat the PLLA nanofiber membrane for 16 hours and the untreated PLLA nanofiber membrane was placed on an infrared spectrometer for detection. As a result, as shown in FIG. 4, it can be seen that the DSPE-PEG-NH was passed only 2 The treated fiber film has characteristic peaks of amide bonds. PLLA in fig. 4 represents an untreated PLLA nanofiber membrane, naOH represents a NaOH-treated PLLA nanofiber membrane, edc\nhs represents an edc\nhs-treated PLLA nanofiber membrane,PLLA-DSPE means passing DSPE-PEG-NH 2 Treated PLLA nanofiber membranes.
Labelling the extracted extracellular vesicles with PKH 26 dye, loading the stained extracellular vesicles on DSPE-PEG-NH 2 The modified PLLA micro-nanofiber membrane and the surface of the PLLA micro-nanofiber membrane which is not modified are rinsed twice with PBS buffer after 6 hours, 200 microliter of PBS buffer is added, 200 microliter of PBS buffer is taken out at the detection time point at 37 ℃ to detect fluorescence value, and new 200 microliter of PBS buffer is added. The detection result is subjected to image J treatment as shown in FIG. 5, and it can be seen that DSPE-PEG-NH is subjected to 2 The release rate of the modified PLLA micro-nanofiber membrane extracellular vesicles is significantly slowed. PLLA-EXO in FIG. 5 represents PLLA micro-nanofiber membranes carrying stained extracellular vesicles; PLLA-DSPE-EXO represents stained extracellular vesicles loaded and passed through DSPE-PEG-NH 2 Modified PLLA micro-nanofiber membranes.
Example 3: application of PLLA micro-nano fiber membrane
The prepared micro-nano fiber membrane is cultured into fibroblasts, and the fibroblasts are taken out and observed at 24h and 48h, and the result is shown in FIG. 6, and the migration condition of the fibroblasts can be seen through DSPE-PEG-NH 2 The modified micro-nanofiber membrane can promote migration of fibroblasts. PLLA-DSPE-EXO in FIG. 6 represents extracellular vesicles loaded and passed through DSPE-PEG-NH 2 A modified PLLA micro-nanofiber membrane; PLLA means neither extracellular vesicles were loaded nor passed through DSPE-PEG-NH 2 A modified PLLA micro-nanofiber membrane; PLLA-DSPE indicated no extracellular vesicles loaded but with DSPE-PEG-NH passed 2 Modified PLLA micro-nanofiber membranes.
Culturing fibroblast and keratinocyte with the prepared micro-nanofiber membrane, taking out and observing proliferation of cells on day 1, day 3 and day 7, and observing the results as shown in FIG. 7a and FIG. 7b 2 The modified micro-nanofiber membrane can promote proliferation of fibroblasts and keratinocytes. FIG. 7a and FIG. 7b show PLLA with neither extracellular vesicles loaded nor DSPE-PEG-NH passed 2 A modified PLLA micro-nanofiber membrane; PLLA-DSPE-EXO represents extracellular vesicles loaded and passed through DSPE-PEG-NH 2 A modified PLLA micro-nanofiber membrane; PLLA-DSPE indicated no extracellular vesicles loaded but with DSPE-PEG-NH passed 2 Modified PLLA micro-nanofiber membranes.
Culturing fibroblasts and macrophages with the prepared micro-nano fiber membrane, taking out the fibroblasts on the 1 st day and the 7 th day, taking out the macrophages on the 2 nd day, and observing the gene expression condition of the cells, wherein the results are shown in FIG. 8a, FIG. 8b, FIG. 8c, FIG. 9a, FIG. 9b, FIG. 9c and FIG. 9d, and can be seen that DSPE-PEG-NH is passed 2 The modified micro-nano fiber membrane can promote the parallel expression of genes related to the wound repair of the fibroblast; promote the expression of macrophage anti-inflammatory gene and inhibit the expression of cell pro-inflammatory gene. The PLLA in FIGS. 8a, 8b, 8c, 9a, 9b, 9c and 9d represent PLLA micro-nanofiber membranes that were neither loaded with extracellular vesicles nor modified with DSPE-PEG-NH2, and PLLA-DSPE represent membranes that were not loaded with extracellular vesicles but were modified with DSPE-PEG-NH 2 Modified PLLA micro-nanofiber membrane, PLLA-DSPE-EXO represents extracellular vesicle loaded and passes through DSPE-PEG-NH 2 Modified PLLA micro-nanofiber membranes.
The above examples are only preferred embodiments of the present invention, and are merely for illustrating the present invention, not for limiting the present invention, and those skilled in the art should not be able to make any changes, substitutions, modifications and the like without departing from the spirit of the present invention.
Claims (5)
1. The application of the micro-nano fiber membrane with the extracellular vesicle slow-release function in preparing a medicine for repairing a chronic wound surface is characterized in that the micro-nano fiber membrane with the extracellular vesicle slow-release function comprises a micro-nano fiber membrane, PEGylated phospholipid and extracellular vesicles; the micro-nano fiber membrane is connected with one end of the PEGylated phospholipid, and the extracellular vesicles are connected with the other end of the PEGylated phospholipid; the micro-nano fiber membrane is an electrospun polymer; the micro-nano fiber membrane is made of L-polylactic acid; the PEGylated phospholipid is a hydrophobic phospholipid connected with a PEG chain; the PEGylated phospholipid is connected with a group on the surface of the micro-nanofiber membrane; the PEGylated phospholipids are capable of intercalating into fines by hydrophobic interactionsIn the lipid bilayer of the extracellular vesicle membrane; the diameter of the micro-nano fiber membrane is 400-2000nm; the chain length of the PEG chain is 500-5000; the group on the surface of the micro-nano fiber membrane is carboxyl; the PEGylated phospholipid is DSPE-PEG-NH 2 。
2. The application of the micro-nanofiber membrane with the extracellular vesicle slow-release function in preparing a medicine for chronic wound repair according to claim 1, wherein the preparation method of the micro-nanofiber membrane with the extracellular vesicle slow-release function comprises the following steps:
(1) Preparing micro-nano fibers by an electrostatic spinning method, and weaving the micro-nano fibers into a micro-nano fiber film;
(2) Carrying out surface modification treatment on the micro-nanofiber membrane in the step (1) to enable groups capable of reacting with PEG phospholipid to be generated on the surface of the micro-nanofiber membrane, and activating the groups to obtain the modified micro-nanofiber membrane;
(3) Soaking the modified micro-nano fiber membrane in the step (2) in a buffer solution containing PEGylated phospholipid, performing grafting reaction in a shaking table, and taking out to obtain the micro-nano fiber membrane with the surface grafted with the PEGylated phospholipid;
(4) And (3) immersing the micro-nano fiber membrane grafted with the PEGylated phospholipid on the surface in the step (3) in a buffer solution containing extracellular vesicles to obtain the micro-nano fiber membrane with the extracellular vesicles slow release function.
3. The application of the micro-nano fiber membrane with the extracellular vesicle slow-release function in preparing a medicine for repairing a chronic wound surface according to claim 2, wherein in the preparation method step (2), the surface modification treatment method is one of a plasma treatment method and a wet chemical method.
4. The application of the micro-nano fiber membrane with the extracellular vesicle slow-release function in preparing a medicine for repairing chronic wounds, according to claim 2, wherein in the preparation method step (3), the concentration of PEGylated phospholipid in the buffer solution containing PEGylated phospholipid is 2-10mg/mL, the pH value of the buffer solution containing PEGylated phospholipid is 5-6, the grafting reaction time is more than or equal to 12 hours, and the rotating speed of a shaking table is 10-60rpm.
5. The use of a micro-nanofiber membrane with an extracellular vesicle slow release function in preparation of a medicine for chronic wound repair according to claim 2, wherein in the preparation method step (4), the concentration of extracellular vesicles in the buffer solution containing extracellular vesicles is 5-15 mug/ml, the pH value of the buffer solution containing extracellular vesicles is 6.8-7.6, the temperature of the buffer solution containing extracellular vesicles is 4-37 ℃, and the time of soaking the micro-nanofiber membrane grafted with PEGylated phospholipids on the surface of the buffer solution containing extracellular vesicles is more than or equal to 4 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165868.9A CN112353815B (en) | 2020-10-27 | 2020-10-27 | Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011165868.9A CN112353815B (en) | 2020-10-27 | 2020-10-27 | Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112353815A CN112353815A (en) | 2021-02-12 |
| CN112353815B true CN112353815B (en) | 2024-02-13 |
Family
ID=74510813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011165868.9A Active CN112353815B (en) | 2020-10-27 | 2020-10-27 | Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112353815B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113088494B (en) * | 2021-04-13 | 2022-08-05 | 武汉大学 | Method for releasing tumor cells captured by erythrocyte biomimetic material |
| CN113388122B (en) * | 2021-06-29 | 2022-09-27 | 上海艾棵颂生物科技有限公司 | Electropositive surface exosome and preparation method and application thereof |
| CN115717279A (en) * | 2022-11-23 | 2023-02-28 | 华南理工大学 | Preparation method of narrow-distribution macromolecular vesicles |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024422A1 (en) * | 2001-09-18 | 2003-03-27 | Vasogen Ireland Limited | Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| CN103751851A (en) * | 2014-01-17 | 2014-04-30 | 东华大学 | Preparation method of inorganic/organic multi-drug controlled release composite nano fiber scaffold |
| CN107158035A (en) * | 2017-05-17 | 2017-09-15 | 天津普瑞赛尔生物科技有限公司 | Treatment bedsore external-use gel containing high concentration human mesenchymal stem cell excretion body extract and preparation method thereof |
| CN110755684A (en) * | 2019-12-10 | 2020-02-07 | 东华大学 | Microsphere/nano yarn composite scaffold loaded with exosome and growth factor and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2803372A1 (en) * | 2013-05-16 | 2014-11-19 | Universiteit Twente | Process for the preparation of an object supporting a lipid bilayer |
-
2020
- 2020-10-27 CN CN202011165868.9A patent/CN112353815B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024422A1 (en) * | 2001-09-18 | 2003-03-27 | Vasogen Ireland Limited | Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| CN103751851A (en) * | 2014-01-17 | 2014-04-30 | 东华大学 | Preparation method of inorganic/organic multi-drug controlled release composite nano fiber scaffold |
| CN107158035A (en) * | 2017-05-17 | 2017-09-15 | 天津普瑞赛尔生物科技有限公司 | Treatment bedsore external-use gel containing high concentration human mesenchymal stem cell excretion body extract and preparation method thereof |
| CN110755684A (en) * | 2019-12-10 | 2020-02-07 | 东华大学 | Microsphere/nano yarn composite scaffold loaded with exosome and growth factor and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| CELL SURFACE ENGINEERING AND ITS APPLICATIONS IN CANCER THERAPY;Daniel Yongwon Lee;https://www.proquest.com/openview/6582fcf347c9e5454a00e2bdd2bca99e/1?pq-origsite=gscholar&cbl=18750&diss=y;第1-242页 * |
| Gene-activated engineered exosome directs osteoblastic differentiation of progenitor cells and induces vascularized osteogenesis in situ;Tianyi Lin et al.;Chemical Engineering Journal;第400卷(第2020期);第1-10页 * |
| The fabrication of a highly efficient self-healinghydrogel from natural biopolymers loaded withexosomes for the synergistic promotion of severewound healing;Chunyao Wang et al.;Biomaterials Science;第8卷;第313-324页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112353815A (en) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112353815B (en) | Micro-nano fiber membrane with extracellular vesicle slow-release function and preparation method and application thereof | |
| Courtenay et al. | Surface modified cellulose scaffolds for tissue engineering | |
| Liu et al. | Composite poly (lactic acid)/chitosan nanofibrous scaffolds for cardiac tissue engineering | |
| Gümüşderelioğlu et al. | A novel dermal substitute based on biofunctionalized electrospun PCL nanofibrous matrix | |
| Fu et al. | Evaluation of bacterial nanocellulose-based uniform wound dressing for large area skin transplantation | |
| Fu et al. | 2D titanium carbide (MXene) nanosheets and 1D hydroxyapatite nanowires into free standing nanocomposite membrane: In vitro and in vivo evaluations for bone regeneration | |
| Ajalloueian et al. | Emulsion electrospinning as an approach to fabricate PLGA/chitosan nanofibers for biomedical applications | |
| Abedi et al. | Concurrent application of conductive biopolymeric chitosan/polyvinyl alcohol/MWCNTs nanofibers, intracellular signaling manipulating molecules and electrical stimulation for more effective cardiac tissue engineering | |
| Pezeshki‐Modaress et al. | Gelatin/chondroitin sulfate nanofibrous scaffolds for stimulation of wound healing: In‐vitro and in‐vivo study | |
| Gutiérrez-Sánchez et al. | RGD-functionalization of PLA/starch scaffolds obtained by electrospinning and evaluated in vitro for potential bone regeneration | |
| Ai et al. | Fabrication of coated-collagen electrospun PHBV nanofiber film by plasma method and its cellular study | |
| Scaffaro et al. | Plasma modified PLA electrospun membranes for actinorhodin production intensification in Streptomyces coelicolor immobilized-cell cultivations | |
| Li et al. | Chitosan and collagen layer-by-layer assembly modified oriented nanofibers and their biological properties | |
| Wu et al. | Fabrication of regenerated wool keratin/polycaprolactone nanofiber membranes for cell culture | |
| Haider et al. | BMP-2 grafted nHA/PLGA hybrid nanofiber scaffold stimulates osteoblastic cells growth | |
| Yuan et al. | Fabrication of protein‐doped PLA composite nanofibrous scaffolds for tissue engineering | |
| Vachiraroj et al. | A comparison of Thai silk fibroin-based and chitosan-based materials on in vitro biocompatibility for bone substitutes | |
| CN103741467A (en) | Preparation method for hyaluronic acid functionalized nano fibers applied to capturing cancer cells in targeted manner | |
| CN112870439A (en) | Nano fiber bone tissue engineering scaffold with core-shell-series crystal structure and preparation method thereof | |
| CN107899086B (en) | Hyaluronic acid oligosaccharide modified collagen nanofiber vascular repair material and preparation method thereof | |
| Meng et al. | Synthesis of gelatin-containing PHBV nanofiber mats for biomedical application | |
| Azizi et al. | Cardiac cell differentiation of muscle satellite cells on aligned composite electrospun polyurethane with reduced graphene oxide | |
| Wang et al. | Preparation and characterization of nano-laponite/PLGA composite scaffolds for urethra tissue engineering | |
| Wan et al. | Submicrofiber‐Incorporated 3D Bacterial Cellulose Nanofibrous Scaffolds with Enhanced Cell Performance | |
| Zhang et al. | The root-like chitosan nanofiber porous scaffold cross-linked by genipin with type I collagen and its osteoblast compatibility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |